Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2024-07-26 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2024 first extraordinary general meeting of shareholders of Yunnan Watson Biotechnology Co., Ltd. It includes information about the meeting date, attendance, voting results on specific proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official voting results and procedural details of the shareholder meeting rather than presenting financial data, management discussion, or other report types. The document is not a full annual or interim report, nor is it a simple announcement of a report publication. It clearly fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2348 characters, which is consistent with a detailed voting results announcement rather than a full report.
2024-07-26 Chinese
北京国枫（上海）律师事务所关于公司2024年第一次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and voting results of the 2024 first extraordinary general meeting (EGM) of shareholders of Yunnan Watson Biotechnology Co., Ltd. It details the legality of the meeting's call, attendance, voting procedures, and results. The document does not contain financial statements or management discussion but focuses on the legal validation of the shareholder meeting and its resolutions. This type of document is a legal proceedings report related to corporate governance and shareholder meetings, not a full annual or interim report, nor a simple announcement. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is under 5,000 characters, but it is a substantive legal opinion, not a mere announcement or certification, so it is not RPA or RNS. Confidence is high due to clear legal opinion content and meeting details.
2024-07-26 Chinese
关于变更回购股份用途并注销及减少公司注册资本暨通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by a company regarding the change in the use of repurchased shares, their cancellation, and the consequent reduction of registered capital. It includes detailed instructions for creditors to declare their claims within a specified period. The document references prior announcements and legal compliance but does not contain financial statements or detailed financial data. It is primarily a notification to creditors about the capital reduction process and related shareholder actions. The document length is short (1573 characters), and it is an announcement rather than a full report. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding capital changes such as share cancellations and capital reduction.
2024-07-26 Chinese
第五届董事会第二十一次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of a board meeting resolution regarding the appointment of a new Chief Financial Officer (CFO). It details the meeting date, voting results, and the biography of the appointed CFO. There is no financial data, earnings information, or detailed report content. The document is a formal announcement of a management change, specifically the appointment of a senior executive. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, not a full report or financial disclosure.
2024-07-22 Chinese
关于召开2024年第一次临时股东大会的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about the convening of the 2024 first extraordinary general meeting (临时股东大会) of Yunnan Watson Biotechnology Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be discussed, registration methods, and proxy forms. The document does not contain financial statements or results but serves as a notice and procedural guide for shareholders to participate in the meeting and vote on specific proposals. It is not a report of financial performance, audit, or earnings, nor is it a transcript or presentation. The document is a formal meeting notice and related procedural information, which fits the category of a shareholder meeting announcement rather than the meeting materials or voting results. Given the content and length (under 5,000 characters), it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the meeting and voting process, not the meeting materials themselves (AGM-R) or voting results (DVA).
2024-07-22 Chinese
关于公司部分高级管理人员变动的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding changes in the company's senior management personnel, detailing resignations and role adjustments of several executives. It includes names, positions, resignation reasons, and shareholdings of the executives. There is no financial data, no mention of financial results, no regulatory certifications, or report publications. The content clearly fits the category of management changes rather than financial reporting or other categories.
2024-07-22 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.